{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:13:26Z","timestamp":1779257606414,"version":"3.51.4"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>While nafamostat mesylate (NM) and sodium citrate serve as commonly used extracorporeal anticoagulants in clinical practice, the characteristics and potential risks of their adverse events (AEs) need to be systematically evaluated. This study comparatively analyzed the reporting characteristics of the AEs of the above-mentioned two drugs based on the World Health Organization Adverse Drug Reaction Reporting Database (WHO-VigiAccess), to identify their safety signals and provide evidence-based guidance for optimizing their clinical uses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Mining of the global AE reporting data of NM and sodium citrate was conducted using the WHO-VigiAccess database, with the data collected until 29 December 2024. Statistical analysis was performed using the Reporting Odds Ratio (ROR), the Proportional Reporting Ratio (PRR), the Bayesian Confidence Propagation Neural Network (BCPNN), and the Empirical Bayes Geometric Mean (EBGM). The signal strengths of the AEs of the two drugs at the system organ class and preferred term levels were systematically evaluated in combination with the standardized coding MedDRA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 1,572 NM-related reports (59 AEs) and 485 sodium citrate-related reports (102 AEs). NM AEs were mainly concentrated in immune system diseases (23.80%), skin and subcutaneous tissue diseases (16.25%), and gastrointestinal diseases (10.10%), with strong disproportionality signals observed for thrombosis in devices (n = 18, ROR = 264.71), shock (n = 119, ROR = 186.27) and anaphylactoid shock (n = 4, ROR = 143.45). In contrast, sodium citrate-related AEs primarily included systemic diseases with various reactions at the administration site (15.75%) and gastrointestinal disorders (11.63%). The reporting proportion of mortality for sodium citrate (2.83%) was higher than that for NM, although this finding may be influenced by reporting bias and confounding by indication. In addition, this study detected signals not described in the instructions, such as citrate toxicity (ROR = 6,740.61) and spinal muscular atrophy (ROR = 665.94). Both drugs shared several high-incidence AEs, including pruritus, vomiting and dyspnea, but there are significant differences in gender, age and geographical distribution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The use of NM was associated with a strong disproportionality signal for severe immune-related AEs, such as anaphylactic shock, and requires strengthened monitoring. The metabolic complications of sodium citrate and its exposure risks during pregnancy require targeted optimization of medication strategies. Real-world data suggested that both drugs may cause AEs that were not mentioned in the instructions, so risk management needs to be improved through dynamic pharmacological vigilance. This study provided important references for individualized selection and safety management of anticoagulation regimens for patients requiring hemodialysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1795980","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:48:48Z","timestamp":1779256128000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Original research a real-world study of adverse events of nafamostat mesylate and sodium citrate based on the world health organization-VigiAccess database"],"prefix":"10.3389","volume":"17","author":[{"given":"Mengting","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First People\u2019s Hospital of Zhangjiagang City","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Science and Education, The First People\u2019s Hospital of Zhangjiagang City","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binbin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First People\u2019s Hospital of Zhangjiagang City","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.trsl.2020.04.014","article-title":"Pathogenesis of heparin-induced thrombocytopenia","volume":"225","author":"Arepally","year":"2020","journal-title":"Transl. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1124\/jpet.122.001248","article-title":"Nafamostat is a potent human diamine oxidase inhibitor possibly augmenting hypersensitivity reactions during nafamostat administration","volume":"382","author":"Boehm","year":"2022","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/s13063-024-08370-9","article-title":"Study on the application of a segmented sodium citrate solution anticoagulation strategy in critically ill patients receiving CRRT: a prospective, randomized controlled study","volume":"25","author":"Chen","year":"2024","journal-title":"Trials"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1093\/ndt\/gfad068","article-title":"Simplified regional citrate anticoagulation protocol for CVVH, CVVHDF and SLED focused on the prevention of KRT-Related hypophosphatemia while optimizing acid-base balance","volume":"38","author":"Di Mario","year":"2023","journal-title":"Nephrol. Dial. Transpl."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1545148","DOI":"10.3389\/fphar.2025.1545148","article-title":"Characteristic analysis of adverse reactions of finerenone: an in-depth analysis from WHO-VigiAccess","volume":"16","author":"Fan","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"6479","DOI":"10.1038\/s41598-023-32795-y","article-title":"Evaluation of the registry DIALYREG for the assessment of continuous renal replacement techniques in the critically ill patient","volume":"13","author":"Gonzalez-Fernandez","year":"2023","journal-title":"Sci. Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s40262-022-01170-x","article-title":"Nafamostat mesylate for treatment of COVID-19 in hospitalised patients: a structured, narrative review","volume":"61","author":"Hernandez-Mitre","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1159\/000045822","article-title":"Anaphylactoid reaction induced by a protease inhibitor, nafamostat mesilate, following nine administrations in a hemodialysis patient","volume":"86","author":"Higuchi","year":"2000","journal-title":"Nephron"},{"key":"B9","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1159\/000517233","article-title":"Regional citrate anticoagulation during double-filtration plasmapheresis in kidney transplant recipients: a single-center retrospective cohort study","volume":"51","author":"Ho","year":"2022","journal-title":"Blood Purif."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e5768","DOI":"10.1002\/pds.5768","article-title":"Adverse drug reaction signal detection methods in spontaneous reporting system: a systematic review","volume":"33","author":"Jiao","year":"2024","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.3390\/jcm9082629","article-title":"Nafamostat mesylate improved survival outcomes of sepsis patients who underwent blood purification: a nationwide registry study in Japan","volume":"9","author":"Kamijo","year":"2020","journal-title":"J. Clin. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijcard.2022.07.022","article-title":"Anticoagulation with nafamostat mesilate during extracorporeal life support","volume":"366","author":"Lang","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e35464","DOI":"10.2196\/35464","article-title":"A data-driven reference standard for adverse drug reaction (RS-ADR) signal assessment: development and validation","volume":"24","author":"Lee","year":"2022","journal-title":"J. Med. Internet. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/1744-9987.13850","article-title":"Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis of randomized controlled trials","volume":"26","author":"Li","year":"2022","journal-title":"Ther. Apher. Dial."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1398783","DOI":"10.3389\/fphar.2024.1398783","article-title":"A real-world data analysis of ocular adverse events linked to anti-VEGF drugs: a WHO-VigiAccess study","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.3324\/haematol.2021.279484","article-title":"Treatment of drug-induced immune thrombocytopenias","volume":"107","author":"Marini","year":"2022","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2024.0615","article-title":"Impact of nafamostat mesylate combined with continuous renal replacement therapy on clinical outcomes, immune function, and oxidative stress markers in patients with sepsis-associated acute kidney injury","volume":"86","author":"Miao","year":"2025","journal-title":"Br. J. Hosp. Med. (Lond)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1007\/s00467-022-05502-8","article-title":"Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy","volume":"37","author":"Miyaji","year":"2022","journal-title":"Pediatr. Nephrol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1476-5381.1994.tb14040.x","article-title":"Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on na+ and K+ transport properties in the rabbit cortical collecting duct","volume":"111","author":"Muto","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.12998\/wjcc.v8.i21.5320","article-title":"Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: four case reports","volume":"8","author":"Okajima","year":"2020","journal-title":"World J. Clin. Cases"},{"key":"B21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.nefro.2018.05.012","article-title":"Sustained severe intestinal edema after nafamostat mesilate-associated anaphylactic reaction during hemodialysis","volume":"39","author":"Shindo","year":"2019","journal-title":"Nefrol. Engl. Ed."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e6140","DOI":"10.1002\/ccr3.6140","article-title":"Cardiopulmonary arrest caused by nafamostat mesylate during hemodialysis","volume":"10","author":"Shioya","year":"2022","journal-title":"Clin. Case Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10047-022-01329-0","article-title":"The effect of citrate in cardiovascular system and clot circuit in critically ill patients requiring continuous renal replacement therapy","volume":"26","author":"Trakarnvanich","year":"2023","journal-title":"J. Artif. Organs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.cell.2024.02.012","article-title":"Generating and using real-world data: a worthwhile uphill battle","volume":"187","author":"Verkerk","year":"2024","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"10760296211050640","DOI":"10.1177\/10760296211050640","article-title":"Treatment effect of regional sodium citrate anticoagulation in elderly patients with high-risk bleeding receiving continuous renal replacement therapy","volume":"27","author":"Xun","year":"2021","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"B26","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/jbcr\/irad196","article-title":"Filter lifespan, treatment effect, and influencing factors of continuous renal replacement therapy for severe burn patients","volume":"45","author":"Yue","year":"2024","journal-title":"J. Burn Care Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1001\/jama.2020.18618","article-title":"Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically ill patients with acute kidney injury: a randomized clinical trial","volume":"324","author":"Zarbock","year":"2020","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13054-023-04519-1","article-title":"Anticoagulation options for continuous renal replacement therapy in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials","volume":"27","author":"Zhou","year":"2023","journal-title":"Crit. Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"Zou","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1795980\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:48:50Z","timestamp":1779256130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1795980\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":29,"alternative-id":["10.3389\/fphar.2026.1795980"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1795980","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"article-number":"1795980"}}